To determine whether atorvastatin, a new HMG‐CoA reductase inhibitor, could be
administered with food in Phase II and III clinical trials, a nonblind, randomized, two‐way …

The pharmacodynamics and pharmacokinetics of atorvastatin, an HMG-CoA reductase
inhibitor, were characterized in 16 healthy subjects following administration of 10 mg …

Tolerance and pharmacokinetics after single‐dose administration of atorvastatin, an
investigational inhibitor of HMG‐CoA reductase, were examined in 22 healthy volunteers in …

This study examined the pharmacokinetics, pharmacodynamics, and safety of atorvastatin,
an investigational inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) …

Atorvastatin is a new 3‐hydroxy‐3‐methylglutaryl‐coenzyme A (HMG‐CoA) reductase
inhibitor that reduces plasma cholesterol by inhibiting cholesterol synthesis and increasing …

The pharmacodynamic effects and pharmacokinetics of atorvastatin, a potent investigational
inhibitor of HMG‐CoA reductase, were studied in 16 normolipidemic subjects after …

The objective of this study is to determine the relationships between plasma atorvastatin
concentrations, LDL (low‐density lipoprotein) cholesterol reduction, and atorvastatin dose; …

HMG-CoA reductase inhibitors or statins are effective in both the primary and secondary
prevention of coronary heart disease, the extent of benefit being proportional to the …

Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease.
Atorvastatin lowers plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of …

Fluvastatin sodium (Lescol) is the first synthetic 3-hydroxy-3-methylglutaryl-coenzyme A
(HMGCoA)-reductase inhibitor to be studied extensively in humans. Absorption of fluvastatin …